Navigation Links
CSL Behring Renews Pledge to Provide Significant Funding and Donated Coagulation Factor to World Federation of Hemophilia Over 3-Year Period
Date:4/16/2012

KING OF PRUSSIA, Pa. and MONTREAL, April 16, 2012 /PRNewswire/ -- To mark World Hemophilia Day 2012, CSL Behring has again committed to making significant financial contributions and donations of clotting factor concentrate to the World Federation of Hemophilia (WFH) Global Alliance for Progress (GAP) program over the period of three years, beginning in 2012. The product donations will be made with medicine having a minimum shelf-life of one year. The goal of the WFH GAP program is to improve the diagnosis and treatment of hemophilia in developing countries. In 2009, CSL Behring was the first company to make such a three-year commitment to WFH. CSL Limited, parent company to CSL Behring, is committed to contributing to the economic, social and environmental well-being of its communities. As part of the agreement, CSL Behring will provide 2 million units of one or more of its various clotting factor products to the WFH each year for three years.

"CSL Behring is proud to be a strong supporter of the World Federation of Hemophilia and to have been a contributor to the GAP program each year since it was established," said Paul Perreault, President of CSL Behring. "We are committed to serving people who have rare and serious bleeding disorders and we will continue to work toward solutions that make a positive impact for hemophilia patients and their communities in regions of the world where those solutions are needed most."

Blood clotting factor is manufactured from purified human plasma or by using recombinant technology.

CSL Behring clotting factor is manufactured in: the Kankakee, IL, USA facility of CSL Behring; in Melbourne, Australia, at the company's Broadmeadows facility, and in Marburg, Germany.

"The product donations we receive from CSL Behring help us to support hemophilia patients in many remote areas of the world where access to these life-saving medicines is extremely challenging," said Mark Skinner, president of WFH. "The reality is that most people with hemophilia or other bleeding disorder do not receive adequate diagnosis, treatment, and management for their conditions. WFH is committed to realizing a day when treatment and sustainable systems to deliver it are available globally in order to close the gap of care for these patients around the world. We certainly appreciate this kind of long-term commitment from CSL Behring. It helps us immeasurably toward that goal."

An estimated one in one thousand women and men has a bleeding disorder.

About the Global Alliance for Progress 
The Global Alliance for Progress (GAP) is a 10-year healthcare development project, launched in 2003. GAP's goal is to greatly increase the diagnosis and treatment of people with hemophilia and other bleeding disorders in developing countries.  The project aims to close the gap between the number of people born with hemophilia and those who reach adulthood, the gap between the estimated and actual number of people diagnosed with hemophilia, and the gap between the amount of treatment product needed versus what is available. To-date, a total of 23,324 patients with hemophilia, 2,423 with von Willebrand disease (VWD) and 1,509 with rare clotting factor deficiencies have been diagnosed/registered through the GAP program.

GAP partners include CSL Behring, the Jan Willem Andre de la Porte Family Foundation, the Irish Hemophilia Society, the World Health Organization (WHO) and other interested parties. GAP country programs are designed to improve five main areas: government support, the care delivery system, medical expertise and diagnosis, quality and quantity of treatment products, and the national hemophilia organization.  At present, there are 12 ongoing GAP countries, including Algeria, Belarus, Ecuador, Lebanon, Moldova, Morocco, Peru, South Africa, Thailand, Tunisia, China, and Syria. Previous GAP countries included Armenia, Azerbaijan, Egypt, Georgia, Jordan, Mexico, the Philippines, and Russia.

About the World Federation of Hemophilia (WFH) 
For 50 years, the World Federation of Hemophilia, an international not-for-profit organization has worked to improve the lives of people with hemophilia and other inherited bleeding disorders. Established in 1963, it is a global network of patient organizations in 118 countries and has official recognition from the World Health Organization. Visit WFH online at www.wfh.org.

About CSL Behring 
CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hereditary angioedema, haemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.com.


'/>"/>
SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery
2. CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS)
3. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
4. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
5. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
6. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
7. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
8. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
9. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
10. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
11. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 The global ... billion by 2025, according to a new study ... anticipated to be predominantly driven by high R&D ... the large-scale production of new and therapeutically advanced ... of drugs at an unprecedented rate into the ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 The ... provides understanding and access to partnering deals and agreements ... - Trends in partnering deals - Top deals by ... stage of development, technology type The report provides ... entered into by the world,s leading healthcare companies. ...
(Date:1/19/2017)... 2017 Conference Call and Webcast to Follow ... it will release results for the fourth quarter of 2016 on ... ... call at 4:30 PM ET on Wednesday, February 15, 2017, during ... financial results and other corporate activities. To participate in the conference ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: ... who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the ... an educator interacting with countless women who had little knowledge of the female characters ...
(Date:1/20/2017)... ... ... a fine examination of how God handles sin, including how to let go of lingering ... for over ten long years has been waiting to release this powerful insight about forgiveness ... been serving the Lord for over twenty years, and he has been preaching and teaching ...
(Date:1/20/2017)... ... ... beautiful and enchanting tale that teaches children the true meaning of Christmas. “Journey to Christmas” ... and a devoted woman of faith. , “Becoming a parent changes you. In my ... mind for years, but actually doing it might have been a while in coming if ...
(Date:1/20/2017)... ... , ... “God's Miracle Man: Against All Odds”: an inspiring affirmation of ... Keith C. A. Tucker, son of Minister Delores Pinnock and a Jamaican native who ... Hardy , “While sitting up in bed, I felt a pounding headache. It was ...
(Date:1/19/2017)... ... , ... Next week after January 20th, the fear for many is that ... health needs of over 30 million. Many interviews with Dr. Carol Francis at the ... servants were suppose to prioritize. Interviews provided below. , Among those present ...
Breaking Medicine News(10 mins):